Ceryvyn Therapeutics Ltd (ASX: CYV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Ceryvyn Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$15.05 million
P/E Ratio
0.04
Dividend Yield
0.00%
Shares Outstanding
1.37 billion
Earnings per share
0.245
Dividend per share
N/A
Year To Date Return
-98.17%
Earnings Yield
2,225.44%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Ceryvyn Therapeutics Ltd (ASX: CYV)
Latest News
Share Fallers
Why IperionX, Northern Star, Opthea, and Superloop shares are tumbling today
Share Fallers
Why Catapult Sports, Harvey Norman, Inghams, and Opthea shares are sinking today
Healthcare Shares
Why is this ASX share crashing 97% today?
Healthcare Shares
Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares
Healthcare Shares
This ASX share potentially 'has no value from here', says broker
Dividend Investing
Why this sold-off ASX All Ords dividend stock is 'well placed to generate long-term shareholder value'
Healthcare Shares
Amid fears of collapse, what's happening with Opthea ASX shares today?
Broker Notes
Experts reveal 4 ASX small-cap shares to buy now
Speculative
Why this speculative ASX stock could rocket 70%
Share Gainers
Why Capricorn Metals, IDP Education, Life360, and Opthea shares are storming higher
Share Fallers
Why Healius, Opthea, Peninsula Energy, and Wildcat shares are falling today
52-Week Highs
3 ASX All Ords health care shares that reached 52-week peaks today
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
CYV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Ceryvyn Therapeutics Ltd
Opthea Limited (ASX: OPT) is a clinical-stage biopharmaceutical company. Following the failure of its Phase 3 wet age-related macular degeneration (AMD) trials, the company discontinued that program and relaunched in June 2026 with a new focus on OPT-302 as a potential treatment for lymphangioleiomyomatosis (LAM), a rare lung disease.
Shareholders have been asked to approve a proposed name change to Ceryvyn Therapeutics to reflect the new direction.
CYV Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 04 Sep 2026 | $0.01 | $0.00 | 0.00% | 1,777,751 | $0.01 | $0.01 | $0.01 |
| 03 Sep 2026 | $0.01 | $0.00 | 0.00% | 7,015,784 | $0.01 | $0.01 | $0.01 |
| 02 Sep 2026 | $0.01 | $0.00 | 0.00% | 514,125 | $0.01 | $0.01 | $0.01 |
| 01 Sep 2026 | $0.01 | $0.00 | 0.00% | 11,643,405 | $0.01 | $0.01 | $0.01 |
| 31 Aug 2026 | $0.01 | $0.00 | 0.00% | 4,765,715 | $0.01 | $0.01 | $0.01 |
| 28 Aug 2026 | $0.01 | $0.00 | 0.00% | 5,823,200 | $0.01 | $0.01 | $0.01 |
| 27 Aug 2026 | $0.01 | $0.00 | 0.00% | 917,775 | $0.01 | $0.01 | $0.01 |
| 26 Aug 2026 | $0.01 | $0.00 | 0.00% | 7,038,965 | $0.01 | $0.01 | $0.01 |
| 25 Aug 2026 | $0.01 | $0.00 | 0.00% | 259,255 | $0.01 | $0.01 | $0.01 |
| 24 Aug 2026 | $0.01 | $0.00 | 0.00% | 10,396,128 | $0.01 | $0.01 | $0.01 |
| 21 Aug 2026 | $0.01 | $0.00 | 0.00% | 219,281 | $0.01 | $0.01 | $0.01 |
| 20 Aug 2026 | $0.01 | $0.00 | 0.00% | 1,054,489 | $0.01 | $0.01 | $0.01 |
| 19 Aug 2026 | $0.01 | $0.00 | 0.00% | 3,066,374 | $0.01 | $0.01 | $0.01 |
| 18 Aug 2026 | $0.01 | $0.00 | 0.00% | 30,285,743 | $0.01 | $0.01 | $0.01 |
| 17 Aug 2026 | $0.01 | $0.00 | 0.00% | 1,018,526 | $0.01 | $0.01 | $0.01 |
| 14 Aug 2026 | $0.01 | $0.00 | 0.00% | 142,000 | $0.01 | $0.01 | $0.01 |
| 13 Aug 2026 | $0.01 | $0.00 | 0.00% | 1,005,144 | $0.01 | $0.01 | $0.01 |
| 12 Aug 2026 | $0.01 | $0.00 | 0.00% | 1,349,717 | $0.01 | $0.01 | $0.01 |
| 11 Aug 2026 | $0.01 | $0.00 | 0.00% | 865,746 | $0.01 | $0.01 | $0.01 |
| 10 Aug 2026 | $0.01 | $0.00 | 0.00% | 1,678,748 | $0.01 | $0.01 | $0.01 |
| 07 Aug 2026 | $0.01 | $0.00 | 0.00% | 4,123,424 | $0.01 | $0.01 | $0.01 |
| 06 Aug 2026 | $0.01 | $0.00 | 0.00% | 322,331 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 23 Jun 2026 | Jeremy Levin | Buy | 13,390,000 | $188,799 |
On-market trade. As per announcement, 3,937 ADRs
|
| 19 Jun 2026 | Jeremy Levin | Issued | 48,000,000 | $672,000 |
Issue of options.
|
| 17 Jun 2026 | Lawrence Gozlan | Sell | 1,877,357 | $28,160 |
On-market trade.
|
| 15 Jun 2026 | Katherine(Kathy) Connell | Buy | 2,000,000 | $30,000 |
On-market trade.
|
| 19 Dec 2025 | Lawrence Gozlan | Issued | 41,000,000 | $24,600,000 |
Directors' share plan. As per annouuncement on 23-12-2025
|
| 19 Dec 2025 | Katherine(Kathy) Connell | Issued | 41,000,000 | $24,600,000 |
Directors' share plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Lawrence Bernard Gozlan | Non-Executive Director | Jul 2020 |
Mr Gozlan a biotechnology investor and advisor, and is the Life Sciences Investment Manager at Jagen Pty Ltd, an international private investment organization. He is also the Chief Investment Officer and Founder of Scientia Capital, a specialized global investment fund focused exclusively on life sciences. Scientia was founded to provide expertise and to manage investments, and more. He is also a member of Risk Committee and Chair of Governance Committee.
|
| Dr Jeremy Levin | Non-Executive ChairmanNon-Executive Director | Oct 2020 |
Dr Levin has served as the Chief Executive Officer of Ovid Therapeutics Inc., and since 2014, as Chairperson of the board of directors, of Ovid. From May 2012 to October 2013, He served as the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company. From September 2007 to December 2012, he held several roles at Bristol Myers Squibb Company, a publicly held pharmaceutical company, ultimately serving as the Senior Vice President of Strategy, Alliances and Transactions. He is also a member of Governance Committee.
|
| Ms Katherine(Kathy) Ellen Danielle Connell | Non-Executive Director | Nov 2024 |
Ms Connell is a healthcare and life sciences leader investment and licensing expertise, delivering deals across pharmaceuticals, medtech, vaccines consumer and digital healthcare for some of the companies. For the past 20 years, she has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors specialising in business development, licensing, acquisitions and venture investment, as well as having worked in healthcare and Life Sciences executive search and management consulting with Korn Ferry. She is member of Risk Committee and Governance Committee.
|
| Mr Hamish George | Chief Financial OfficerJoint Company Secretary | Oct 2025 |
-
|
| Ms Stephanie Vipond | Joint Company Secretary | Oct 2025 |
-
|
| Judith Robertson | Chief Commercial Officer |
-
|
|
| Tom Reilly | Chief Financial Officer |
-
|
|
| Hamish George | Chief Financial OfficerJoint Company Secretary |
-
|
|
| Parisa Zamir | Chief Medical Officer |
-
|
|
| Megan Baldwin | Founder Chief Innovation Officer and Executive Director |
-
|
|
| Stephanie Vipond | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 194,136,944 | 15.77% |
| Citicorp Nominees Pty Limited | 183,915,116 | 14.94% |
| Ubs Nominees Pty Ltd | 166,500,018 | 13.52% |
| Jp Morgan Nominees Australia Pty Limited | 138,447,073 | 11.24% |
| BNP Paribas Noms Pty Ltd | 53,851,264 | 4.37% |
| HSBC Custody Nominees(Australia) Limited Gsco Eda | 47,047,963 | 3.82% |
| HSBC Custody Nominees (Australis) Limited A/C2 | 44,858,465 | 3.64% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 40,072,530 | 3.25% |
| Merrill Lynch(Australia) Nominees Pty Limited | 35,396,820 | 2.87% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 19,689,961 | 1.60% |
| Information Logistics Pty Ltd <Information Logistics A/C> | 18,076,530 | 1.47% |
| National Nominees Limited | 16,523,839 | 1.34% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 10,336,919 | 0.84% |
| Jadeglen Investments Pty Ltd <David Thurin Family A/C> | 9,004,711 | 0.73% |
| Safo Investments Pty Ltd <Safo Investment A/C> | 8,134,875 | 0.66% |
| M & S Skyleisure Pty Ltd, M & S Skyleisure No 2 A/C> | 6,581,336 | 0.53% |
| M & S Skyleisure Pty Ltd, M & S Skyleisure No 1 A/C> | 6,581,335 | 0.53% |
| BNP Paribas Noms (Nz) Ltd | 6,410,388 | 0.52% |
| Armada Trading Pty Limited | 5,005,806 | 0.43% |
| Jadeglen Investments Pty Ltd <David Thurin Family A/C> i | 5,000,000 | 0.41% |
